Discontinuation of medications for alcohol use disorder in the United States: Patient, prescriber and medication predictors
Addiction · 2026
DOI: 10.1111/add.70498 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Addiction, 2026. Verfasst von Alisa B Busch und 6 weiteren Autor:innen. Beteiligte Einrichtung: McLean Hospital, Mass General Brigham Department of Psychiatry, Harvard Medical School, Belmont, MA, USA. Hauptthemen laut MEDLINE: Alcohol Deterrents, Alcoholism, Drug Monitoring. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAAA NIH HHS, United States National Institute on Alcohol Abuse and Alcoholism (NIAAA).
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Background and aims Little is known about medication for alcohol use disorder (MAUD) adherence. The goal of this study was to examine patient, prescriber and medication characteristics associated with time to discontinuation of MAUD. Design, setting and participants Observational cohort study from Optum Labs de‐identified administrative claims data of a United States national sample of commercial and Medicare Advantage enrollees with alcohol use disorder (AUD) who initiated MAUD (naltrexone, acamprosate, disulfiram, topiramate) January 2017–June 2024 ( n = 51 915). Using an accelerated failure time (AFT) log logistic survival model, we examined MAUD discontinuation, adjusting for patient demographic and clinical characteristics established within 6 months prior to or on date of initiation, specific MAUD initiated with, MAUD prescriber type and study year. We defined effect size of at least 10% change in AFT survival (i.e. AFT estimates > +/− 0.100) as being of clinical significance.
Measurements
Time‐to‐discontinuation of MAUD, defined as a gap in pharmacy fills or medication administrations of MAUD days‐supply >7 days.
Findings
In unadjusted analyses, the median time to MAUD discontinuation was 30 days; median days‐supply prior to discontinuation varied by medication (e.g. 30 days for acamprosate and naltrexone, 56 for disulfiram, 60 for topiramate). Adjusted analyses showed that among the patient characteristics, longer MAUD duration was associated with older age [e.g. AFT duration estimate (95% confidence interval) for age ≥65 vs. 18–30 = 0.164 (0.088–0.240)], while lower county median household income was associated with shorter duration [e.g.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- McLean Hospital, Mass General Brigham Department of Psychiatry, Harvard Medical School, Belmont, MA, USA.
- Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.
- Heller School for Social Policy and Management, Brandeis University, Waltham, MA, USA.
- Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
- RAND Corporation, Arlington, VA, USA.
ORCID-Profile: Alisa B Busch
Förderung
- NIAAA NIH HHS
- United States National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Zitieren
APA
Busch, A. B., Hodgkin, D., Kennedy-Hendricks, A., Ritter, G. A., Uscher-Pines, L., Horgan, C. M., & Huskamp, H. A. (2026). Discontinuation of medications for alcohol use disorder in the United States: Patient, prescriber and medication predictors. Addiction. https://doi.org/10.1111/add.70498
Vancouver
Busch AB, Hodgkin D, Kennedy-Hendricks A, Ritter GA, Uscher-Pines L, Horgan CM, et al. Discontinuation of medications for alcohol use disorder in the United States: Patient, prescriber and medication predictors. Addiction. 2026. doi:10.1111/add.70498
BibTeX
@article{Busch2026,
author = {Busch, Alisa B and Hodgkin, Dominic and Kennedy-Hendricks, Alene and Ritter, Grant A and Uscher-Pines, Lori and Horgan, Constance M and Huskamp, Haiden A},
title = {Discontinuation of medications for alcohol use disorder in the United States: Patient, prescriber and medication predictors},
journal = {Addiction},
year = {2026},
doi = {10.1111/add.70498}
}
EUVIMED